原研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 类风湿关节炎 | 临床1期 | 中国 | 2026-01-08 | |
| 系统性红斑狼疮 | 临床1期 | 中国 | 2024-07-20 | |
| 白血病 | 临床1期 | 中国 | 2022-08-22 | |
| 淋巴瘤 | 临床1期 | 中国 | 2022-08-22 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床1期 | 中国 | 2021-06-07 | |
| 复发性B细胞淋巴瘤 | 临床1期 | - | 2019-09-15 | |
| 难治性B细胞淋巴瘤 | 临床1期 | - | 2019-09-15 | |
| 弥漫性大B细胞淋巴瘤 | 临床1期 | 中国 | 2019-09-10 | |
| 边缘区B细胞淋巴瘤 | 临床1期 | 中国 | 2019-09-10 | |
| 急性淋巴细胞白血病 | 临床申请批准 | 中国 | 2026-01-14 |
临床1期 | 6 | 範夢獵蓋鏇遞網夢壓糧(選鏇鑰製衊餘獵膚製餘) = All patients had grade I-II fever (drug-related) during the treatment. No other drug-related adverse events were observed including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), myelotoxicities, hypogammaglobulinemia or infections. 範簾壓壓壓糧範窪鏇衊 (築觸艱構窪蓋淵淵築夢 ) | 积极 | 2024-11-10 | |||
临床1期 | 6 | 鏇鹹範構鹹範艱築壓淵(廠廠廠襯夢築構夢簾範) = All patients had grade I-II fever (drug-related) during the treatment. No other drug-related adverse events were observed. 夢壓築襯範襯鹹餘鹽衊 (鹹鹽鑰壓選觸獵顧艱遞 ) 更多 | 积极 | 2024-10-24 |






